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Introduction
As many as 30% of patients with breast cancer who have
undergone curative surgery and show no evidence of
locoregional or distant disease still have recurrent disease
over 5–10 years [1,2]. Some of these treatment failures
may be attributed to residual disease in the breast or axil-
lary lymph nodes [3]. The limitation of routine histopatho-
logic examination of the tumor margins and the dissected
lymph node specimen is well known [4]. Contemporary
methods of detection, including computed tomography,
magnetic resonance imaging, bone scintigraphy and flow
cytometry, all have limited sensitivity and specificity [5,6].
Micrometastases can be found by immunohistochemistry
or polymerase chain reaction in 10–30% of the patients
previously deemed free of disease by conventional histo-
logical methods [7,8]. The prognostic importance of
ER = estrogen receptor; HGFA = hepatocyte growth factor activator; HGF/SF = hepatocyte growth factor/scatter factor; PR = progesterone
receptor; RT–PCR = reverse transcriptase–polymerase chain reaction.
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Abstract
Background: The diverse biological effects of hepatocyte
growth factor/scatter factor (HGF/SF) are mediated by c-Met,
which is preferentially expressed on epithelial cells. Met signaling
has a role in normal cellular activities, and may be associated
with the development and progression of malignant processes.
In this study we examined whether Met can be detected in the
axillary drainage from patients who underwent conservative
operations for breast cancer, and its prognostic significance.
Methods: Thirty-one consecutive patients with invasive ductal
carcinoma of the breast suitable for breast-conserving
treatment were studied. The output of the drain that had been
placed in the axilla during the operation was collected, and the
presence of Met and β-actin were assessed by reverse
transcriptase–polymerase chain reaction (RT–PCR) assays.
The data were compared with the pathological features of the
tumor and the axillary lymph nodes, and with the estrogen
receptor and progesterone receptor status.
Results: RT–PCR of the axillary lymphatic drainage was
positive for Met in 23 (74.2%) of the patients. Positive assays
were correlated with increasing tumor size and grade, with
capillary and lymphatic invasion, and with lymph node
metastasis (P<0.02, for all comparisons). All 12 patients with
axillary lymph node metastases had positive assays for Met,
compared with 57.9% of patients without lymph node
metastases. All five patients with tumor involvement in the
margins of the resection had positive assays for Met in their
lymphatic fluid, compared with 18 of 26 positive assays
(69.2%) for patients without involved margins (P<0.04).
Finally, Met showed negative correlations with positivity for
estrogen receptor and progesterone receptor (P<0.02).
Conclusion: Met can be detected in the axillary fluids of
patients with breast cancer and its expression in the axillary
drainage may have potential as a prognostic factor. This finding
might be relevant to therapeutic considerations, because a
positive assay for Met in histologically node-negative patients
might point to the need to search for node microinvasion or
involvement of the excision margins with tumor.
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micrometastases found with these sensitive methods are
now being evaluated [9–11].
Hepatocyte growth factor/scatter factor (HGF/SF) is a
paracrine factor produced primarily by mesenchymal cells.
HGF/SF induces mitogenic and morphogenic changes,
including rapid membrane ruffling, formation of micro-
spikes, and increased cellular motility [12,13]. The diverse
biological effects of HGF/SF are all mediated by Met,
which is preferentially expressed on epithelial cells [14].
In vivo this receptor–ligand pair is essential for normal
embryonic development [15,16]. Whereas Met signaling
clearly has a role in normal cellular processes, this signal-
ing pathway has also been implicated in tumor develop-
ment and progression. Met signaling can increase
tumorigenicity, induce cell motility, and enhance invasive-
ness in vitro and metastasis in vivo [14,17–20]. In addi-
tion, Met signaling can increase the production of
protease and urokinase, which are associated with extra-
cellular matrix/basal membrane degradation and are
important for metastasis [14,19].
Operations for breast cancer include either mastectomy or
breast-conserving surgery, consisting of wide local exci-
sion of the tumor with margins of intact breast tissue
(‘lumpectomy’) and axillary lymph node dissection. Drains
are inserted in the dissected axilla in most of these opera-
tions, to avoid the accumulation of lymphatic fluid. The
goals of this study were to examine whether Met can be
detected by reverse transcriptase–polymerase chain reac-
tion (RT–PCR) in the axillary drainage from patients who
have undergone conservative operations for breast
cancer, and to assess the correlations between the mRNA
expression of Met in the collected fluid and prognostic
factors of breast cancer.
Materials and methods
Patients and operations
Thirty-one consecutive women with invasive ductal carci-
noma of the breast, who were suitable for breast-conserv-
ing treatment, were studied. We included only patients
who underwent conserving breast surgery so that we
could evaluate the correlations of Met–HGF/SF expres-
sion with both the tumor margins and the status of the axil-
lary lymph nodes. The diagnosis of cancer was
established by needle core biopsy (‘Trucut’), which was
performed 2 weeks before the operation. All patients
underwent wide local excision and axillary lymph node dis-
section by the same team. Non-palpable tumors were
localized by mammography before surgery by wire inser-
tion. During operations a wide resection around the wire
was performed, followed by mammographic confirmation
of complete resection of the tumors. The axillary dissection
was performed with a separate incision, and level I and II
axillary lymph nodes were removed. The breast incisions
were closed without drainage, and all axillae were drained
postoperatively by closed vacuum drains (ch-14; Bio-
metrix). The output of the drain was collected and mea-
sured every 24 hours; the drains were removed when the
output was less than 25ml per 24h. The presence of
Met–HGF/SF and β-actin were assessed in the fluid,
which was collected during the second postoperative day
because during the first 24hours it might contain many
erythrocytes and debris.
Pathological examinations
The resected specimen was covered circumferentially by
black Indian ink and Bouins solution and then was sliced
into 5mm slices. Each slice was evaluated macroscopi-
cally for the presence of tumor and its distance from the
margins of the specimen. All slices involved with tumor
were paraffin embedded, sliced again into 4µm slides,
and stained with hematoxylin–eosin. Microscopical evalua-
tion was performed by one pathologist for margin involve-
ment, tumor type, size, grade, capillary or lymphatic
invasion, and the distance from the margins. All axillary
lymph nodes were paraffin embedded, sliced into 4µm
slides and assessed for the presence of micrometastases.
Receptor assays
Estrogen receptor (ER) and progesterone receptor (PR)
were assessed in the tumor by immunohistochemical
assay with mouse monoclonal antibodies (NCL-ER-6F11
and NCL-PGR-312) in accordance with the manufactur-
er’s instruction (Novocastra Laboratories). We used the
‘quick score’, a simple combination of the proportion of
cells staining plus a measure of intensity of staining [21].
A cut-off value of 2 or more was taken as negative for ER
or PR.
RT–PCR assays
Total RNA was extracted from axillary lymphatic fluid with
the Tri Reagent procedure, in accordance with the manu-
facturer’s instruction (Sigma). Reverse transcription was
performed with 1–2µg of total RNA. The first strand of
cDNA was generated with 0.5µg of (dT)15 primer
(Gibco–BRL) using 200 units of subscripts II RNAse-
H–reverse transcriptase (Gibco–BRL). This was incu-
bated for 50 min at 42°C, followed by inactivation for
15 min at 70°C. To detect Met transcript, PCR was
performed on 3µl of cDNA with MP1 primer (5′-
GGAATCGAGCTGCGAGA-3′) and MP2 primer (5′-
TCCAACATGCAGTTTCTTGC-3′). To detect β-actin
transcript, PCR was performed on 3µl of cDNA with MP1
primer (5′-CTCTTCCAGCCTTCCTTCCT-3′) and MP2
primer (5′-AGCACTGTGTTGGCGTACAG-3′). Cycling
conditions consisted of 35 cycles with denaturation steps
at 94°C for 30s, hybridization steps at 55°C for 30s and
an extension step at 72°C for 1 min. The β-actin and c-Met
RT–PCRs were performed simultaneously, under the
same conditions. The limit of sensitivity of the RT–PCR
system for Met was 1pg of total RNA.R73
Immunohistochemical analyses
Staining was performed with an antibody against hepato-
cyte growth factor-α receptor (HGFα-R; H-145; Santa
Cruz Biotechnology, Santa Cruz, California, USA). Sec-
tions (5µm) mounted on Super Frost/plus glass (Menzel
and Claser, both in Braunschweig, Germany), were
processed by a labelled streptavidin–biotin method with a
Histostain Plus kit (Zymed, San Francisco, California,
USA). Heat-induced antigen retrieval was performed by
temperature-controlled microwave treatment with an
H2800 model processor (Energy Beam Sciences Inc,
Agawan, Massachusetts, USA) for 12 min in 10mM
citrate buffer, pH 6.0, at 97°C. The sections were treated
for 5 min with 3% H2O2, followed by a 10 min incubation
with the universal blocker, Cas-block (Zymed). The sec-
tions were incubated for 32 min with 1:20 diluted
HGFα-R antibody. A biotinylated second antibody was
applied for 10 min, followed by incubation with horserad-
ish peroxidase-conjugated streptavidin for 10 min. The
slides were washed with Optimax wash buffer (BioGenex,
San Ramon, California, USA) after each incubation. The
immunoreaction was revealed by a horseradish peroxi-
dase-based chromogen. The sections were then counter-
stained and cleared in xylene. Controlled staining was
performed with human liver tissue. The presence of brown
(diaminobenzidine) staining of the cell membranes of
tumor cells was interpreted as positive reactivity.
Control group
To verify that in normal persons there is no Met in the
axilla we examined the axillary drainage in 20 patients
with malignant melanoma who were found to have nega-
tive axillary sentinel lymph node. The lesions were
located in the upper limbs, and the lymph node basins
were found to be in the axilla. Sentinel lymph nodes were
found in all these patients and none was involved with
melanoma in frozen sections or in paraffin-embedded
and stained slices.
Statistical evaluation
Correlations between the various clinicopathological para-
meters and RT–PCR assays in lymphatic fluid were ana-
lyzed by the χ2 test (P<0.05).
Results
Thirty-one consecutive female patients who underwent
breast-conserving surgery for operable invasive duct car-
cinoma of the breast between 1 January and 30 June
2000 were included. Patients with tumors that invaded
the chest wall or skin, or with inflammatory carcinoma,
were excluded. The mean age was 58±16 years.
Twenty-three patients (74.2%) underwent lumpectomy
for palpable masses, and in eight women (25.8%) wire-
guided excision of non-palpable tumors was performed.
The tumor size was 0–1cm in 10 women (32.2%),
1–2cm in 9 (29.0%), 2–5cm in 11 (35.4%), and larger
than 5cm in 1 (3.2%). Four patients (12.9%) had grade I
tumors, 19 (61.3%) had grade II lesions, and grade III
tumors were found in 8 (25.8%). Lymphatic and capillary
invasion were noted in 10 (32.2%) and 11 (35.4%)
patients, respectively. While attempting to achieve free
margins, five patients (16.1%) had to undergo re-excision
owing to incomplete resections. Two of these patients
had wire-guided excisions.
The collected axillary fluids were assessed by RT–PCR for
Met and β-actin. The β-actin RT–PCR served as positive
control and gave strong signals in all cases, indicating that
both RNA preparation and cDNA synthesis were success-
ful. The RT–PCR assays were positive for Met in 23
(74.2%) of the breast cancer patients (Fig.1). In all of the
patients in the control group, RT–PCR gave positive
results for β-actin but was negative for Met.
The correlations between tumor size and the presence of
Met in the axillary fluid are shown in Table 1. Positive
RT–PCR assays for Met in the lymphatic fluids were asso-
ciated with increasing tumor size. Eleven of 19 patients
(57.9%) with T1 tumors (tumor size 0–2cm) had positive
Met in the axillary fluid (50% and 66% for tumors 0–1 and
1–2cm in size respectively), compared with 12 of 12
patients (100%) with T2 and T3 tumors (P<0.01).
The average number (±SD) of axillary lymph nodes was
17±4, and all dissected nodes were examined for the
presence of metastases. Twelve patients (38.7%) had axil-
lary lymph node metastases as revealed by
hematoxylin–eosin staining. The correlation between
metastatic axillary lymph node involvement and the pres-
ence of Met in the lymphatic fluid is shown in Table 2. All
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Figure 1
Reverse transcriptase–polymerase chain reaction (RT–PCR)
amplification of Met and β-actin mRNA obtained from lymphatic fluids
from women with breast cancer. Met and β-actin expression were
examined by RT–PCR, and the results of agarose-gel electrophoresis
of some of the patients are shown.12 patients with axillary lymph node metastases had posi-
tive RT–PCR assays for Met, compared with 57.9%
(11 of 19) positive assays for women without lymph node
metastases (P<0.01).
All five patients with tumor involvement in the margins of
the resection had positive RT–PCR assays for Met in their
lymphatic fluid, compared with 18 of 26 positive assays
(69.2%) for patients without involved margins (P<0.04).
The associations between tumor grade, capillary and lym-
phatic invasion, and the presence of Met in the axillary
fluid are presented in Table 3. Patients with lymphatic
invasion of the tumor were all Met-positive (10 of 10), and
patients without lymphatic invasion had 61.9% (13 of 21)
positive assays for Met (P<0.02). Capillary invasion of the
tumor was also found to be in correlation with Met;
although all 11 patients with capillary invasion had positive
RT–PCR assays for Met in their axillary fluid, the assays
were positive in only 60% (12 of 20) patients without cap-
illary invasion (P<0.02). The presence of Met in the axil-
lary drainage was also correlated with higher tumor grade:
it was found in 50% of grade I tumors, compared with
87.5% of grade III lesions (P<0.05).
The correlations between the ER and PR status and
RT–PCR assays for Met in the axillary fluid are shown in
Table 4. Seventeen patients had ER-negative tumors, and
16 (94.1%) of these had Met-positive assays in the axillary
fluid. In seven (87.5%) of the eight patients with Met-neg-
ative assays the ER were positive. Similarly, 21 patients
had PR-negative tumors, and 20 (95.2%) of these were
positive for Met. PR-positive tumors were found in seven
of eight patients (87.5%) in whom assays for Met in the
axillary drainage were negative.
All the paraffin-embedded sections of the resected
primary breast cancers were assessed by immunohisto-
chemistry staining for Met. In 28 patients (90.3%) the
primary tumor stained positively for Met and none of the
tumors that had negative staining had a positive Met
RT–PCR assay in the axillary drainage. In addition, the
patients with negative staining had no involvement of
lymph nodes.
Discussion
HGF/SF is synthesized as a pro-HGF, and once activated
by the HGF activator (HGFA), the complex HGF/SF–Met
affects numerous normal cellular processes [22].
HGF/SF–Met is also involved in malignant transformation,
presumably as a mediator in interaction between tumor
and stroma, which enhances tumor progression, and also
angiogenesis [23,34]. In invasive ductal carcinoma,
stronger expression of HGF/SF seems to be associated
with tubule formation [25]. HGF/SF is overexpressed in
breast carcinoma in situ and invasive ductal carcinoma in
comparison with normal breast tissue. Normal mammary
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Table 1
Correlation between Met status and tumor size
Tumor size (cm) Met-positive patients (%)
0–1 5/10 (50)
1–2 6/9 (66)
2–5 11/11 (100)
> 5 1/1 (100)
Table 2
Correlation between Met status and axillary lymph node
involvement
Lymph node involvement Met-positive patients (%)
None 11/19 (57.9)
1–3 8/8 (100)
4–10 4/4 (100)
Table 3
Correlation between Met status, capillary and lymphatic
invasion and tumor grade
Measure Status Met-positive patients (%)
Capillary invasion Present 11/11 (100)
Absent 12/20 (60)
Lymphatic invasion Present 10/10 (100)
Absent 13/21 (61.9)
Grade I 2/4 (50)
II 14/19 (73.6)
III 7/8 (87.5)
Table 4
Correlation between Met status, estrogen receptor and
progesterone receptor
Receptor status Met-positive patients (%)
ER-positive 7 /14 (50)
ER-negative 16/17 (94.1)
PR-positive 3/10 (30)
PR-negative 20/21 (95.2)
ER, estrogen receptor; PR, progesterone receptor.ducts within infiltrating cancer showed intermediate levels
of HGF/SF. This finding suggests that the expression of
these proteins in breast cancer is regulated by soluble
factors produced by the tumor cells [26,27]. High levels of
expression of HGF and Met are associated with invasive
breast cancer, and might be causally linked to early recur-
rences, metastatic disease and shortened survival of
breast cancer patients [28,29]. High levels of HGF/SF
detected within breast tumor extracts are correlated with
larger tumor size and shorter relapse-free and overall sur-
vival compared with tumors with low HGF/SF concentra-
tion [30].
The activation of HGF/SF by HGFA might be modified by
the two HGFA inhibitors, HAI-1 and HAI-2. Highly invasive
breast cancer cells express large amounts of HGF and
Met, and no HAI-1, whereas breast cancer cells with low
invasive potential have low levels of HGF and Met, and
high levels of HAI-1 [22]. In a mouse model system HGF
antagonists suppressed the conversion of pancreatic
tumors from carcinoma in situ into invasive cancer [23]. It
seems that regulation of the HGF/SF stimulation and inhi-
bition activities is associated with the metastatic potential
of tumor cells, and knowing the status of HGFA, HAI-1
and HAI-2, in addition to Met, might provide useful infor-
mation.
HGF/SF and Met have been found in a variety of tumors
[31–33], and in lymph nodes of patients with no tumor
[34], but never in the fluid drained from the tumor bed
or the lymph node basin. In this study we evaluated
whether Met can be detected in the axillary drainage of
breast cancer patients, and the significance of its
expression in the lymphatic fluid. Studying the expres-
sion of Met in the axillary fluid is a simple, non-invasive
procedure because drains are routinely inserted during
axillary lymph node dissections. The collected fluid is
readily available, and RT–PCR is a routine, short assay
with minimum artefacts.
The axillary fluid after breast and axillary lymph node oper-
ations includes erythrocytes, lymphocytes, epithelial cells
and tumor cells. One of the goals of this work was to
examine whether tumor cells can be detected in the axil-
lary drainage by RT–PCR assays for Met. To determine
the source of Met in the axillary fluid in breast cancer
patients and to exclude the possibility that the source was
related to surgical trauma, we evaluated a control group of
melanoma patients with negative axillary sentinel lymph
nodes. In none of the control patients was the axillary
drainage Met-positive. In 28 patients the primary tumor
stained positively for Met and none of the tumors that had
negative immunostaining had a positive Met RT–PCR
assay in the axillary drainage. Thus, it seems likely that the
source of Met in the axillary fluid in node-negative breast
cancer patients is the tumor in the breast.
The results show that Met can be detected in the axillary
drainage, and although the number of patients was not
high, Met is associated with unfavorable prognostic
factors. Positive assays for Met are correlated with tumor
size, grade, lymphatic invasion, tumor involvement of the
margins of the resected specimen, the existence of metas-
tases in the lymph nodes, and the numbers of lymph
nodes with tumor. Met was associated with larger tumors,
and in none of the patients with tumors larger than 2cm
was the assay negative. Moreover, Met was never nega-
tive in patients with metastatic carcinoma in the lymph
node. Negative staining for ER and PR is associated with
unfavorable prognosis, and the assays for Met in the axil-
lary fluid were positive in most receptor-negative tumors.
One could postulate that because Met was highly corre-
lated with tumor size, its expression implies aggressive
behavior of the malignant processes. The significance of
HGF/SF as a marker of poor prognosis might also be
associated with its effects on acquired resistance to anti-
cancer drugs [35,36]. HGF/SF protects cancer cells from
DNA-damaging chemotherapy agents through pathways
involving signaling from Met to phosphoinositide 3-kinase
and c-Akt [29]. Human breast cancer cells, preincubated
with HGF/SF and then exposed to Adriamycin, exhibit an
altered pattern of gene expression compared with cells
treated with Adriamycin alone. Cells treated with HGF/SF
and Adriamycin also had modified cell line regulation and
signal transduction that might suggest mechanisms by
which HGF/SF exerts its protective activity [31].
To our knowledge, this is the first report of the expression
of Met in the axillary drainage in patients who have under-
gone operations for breast cancer. The results suggest
that the expression of Met in the axillary drainage might
have prognostic significance. More importantly, its expres-
sion in histologically node-negative patients point to the
need to search for node micrometastasis or involvement of
the excision margins by tumor. Therefore, RT–PCR for Met
in the axillary fluid of patients who undergo breast-con-
serving surgery for breast cancer could influence therapy.
The results of this study justify prospective investigation
on a larger scale, and the clinical significance of Met posi-
tivity in the axillary drainage fluid in breast cancer patients
should be defined by an extended follow-up study.
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